Sysmex (6869) · InitiativeRestated
Commercialization of iPS cell-derived platelet products through the acquisition of MegaCarion as a subsidiary
First written in FY2024-Q3. 1 of 2 entries say "Restated". Latest entry: FY2024.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Commercialization of iPS-derived platelet products through the acquisition of メガカリオン as a subsidiaryA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024RestatedAnnual report
「In December 2023, to accelerate initiatives in the regenerative cellular medicine field, the Company acquired additional shares in Megakaryon Inc., which has platform technology for producing platelets from human iPS cells, making it a consolidated subsidiary.」
Reiterates the consolidation of Megakaryon as a subsidiary and the acceleration of commercialization of iPS cell-derived platelet products. - FY2024-Q3First statedAnnual report
「In December 2023, to accelerate initiatives in the regenerative cellular medicine field, the Company acquired additional shares in Megakaryon Inc., which has platform technology for producing platelets from human iPS cells, making it a consolidated subsidiary.」
Acquired additional shares in Megakaryon and made it a consolidated subsidiary, beginning efforts to accelerate the commercialization of iPS cell-derived platelet products. Also considering their application as raw materials for reference materials used in quality control of testing instruments.